Despite the treatments available for heart failure, hospitalization and mortality rates remain high. Optimized heart failure management is the key to improved patient outcomes and quality of life.1,3,4 With over 20 years of clinical evidence, Roche NT-proBNP provides support throughout the continuum of care in heart failure.5-6
Elecsys® proBNP II
IVD
For in vitro diagnostic use.
Despite the treatments available, hospitalization and mortality rates remain high.1
NT-proBNP has analytical advantages over BNP
View Full TableNT-proBNP has analytical advantages over BNP
| Characteristics | BNP | NT-proBNP 7 | NT-proBNP Advantages 7 |
|---|---|---|---|
| Half-life | 20 minutes |
60-120 minutes
|
Less prone to intra-day variability8 |
| Stability | Varies 4-24 hours at room temperature |
Up to 3 days at room temperature
|
Greater stability enables lab flexibility for outreach and add-on testing |
BNP assays are not standardized across manufacturers
NT-proBNP assays, unlike BNP, are standardized across manufacturers. In the Emergency Department and inpatient and outpatient settings, consistent results allow for more confidence in heart failure management.
Clinical excellence
NT-proBNP delivers confidence when managing patients across the heart failure spectrum.
Would you like to know more about the Elecsys® proBNP II assay?
Please submit your information in the following form to be contacted by a Roche representative with more details.
When a patient presents with heart failure, will you know EVERY medication they’re taking?
Some biomarkers are affected by certain medications. For instance, if a patient is taking an ARNI (angiotensin receptor-neprilysin inhibitor), BNP levels will appear elevated, potentially leading to erroneous treatment. Using NT-proBNP, levels of which are not affected by neprilysin, you can ensure you will have the most accurate clinical picture to provide the best patient care.8
References
- World Heart Failure Alliance. White Paper: Heart failure, preventing disease and death worldwide. Web: https://www.escardio.org/static_file/Escardio/Subspecialty/HFA/WHFA-whitepaper-15-May-14.pdf. Accessed May 2023.
- Piotr Ponikowski-Heart Failure- Preventing Disease and Deth Worldwide\World Heart Failure Alliance.
- Cowie, M.R. et al. (2013) Improving care for patients are acute heart failure. Retrieved from: http://www.oxfordhealthpolicyforum.org/reports/acute-heart-failure/improving-care-for-patients-with-acute-heart-failure. Accessed May 2023.
- Krumholz HM, et al. (2009). Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes.;2(5):407-413
- Francis et al. (2016). J Am Coll CArdil. 67(3), 330 – 337
- PubMed Central®: search results for “Roche NT-proBNP heart failure”. Accessed on January 2018
- Reference: Elecsys NT-proBNP Package Insert
- Emdin M. Clin Chem. 2007;53:71289-71297.
